We are live on ! Find out more
PSC

Patient Square Capital Portfolio holdings

AUM $564M
1-Year Est. Return 261.3%
This Fund
S&P 500
This Quarter Est. Return
+79.9%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$374M
AUM Growth
+$96.5M
Cap. Flow
-$11M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.56%
Holding
27
New
8
Increased
6
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$9.31M
2
CDTX
Cidara Therapeutics
CDTX
+$6.76M
3
CELC icon
Celcuity
CELC
+$4M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$3.19M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.98M

Top Sells

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$13.4M
2
ARGX icon
argenx
ARGX
+$8.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$6.54M
4
SRRK icon
Scholar Rock
SRRK
+$5.45M
5
INSM icon
Insmed
INSM
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.5B
$189M 50.51%
12,480,000
– –
INSM icon
2
Insmed
INSM
$21.4B
$47M 12.57%
326,400
-32,400
-9% -$3.97M
EYPT icon
3
EyePoint Inc
EYPT
$1.04B
$14.4M 3.85%
1,011,839
-340,998
-25% -$3.93M
ABVX
4
Abivax
ABVX
$10.9B
$12.9M 3.45%
+151,833
New +$9.31M
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
$11.6M 3.1%
121,000
+106,000
+707% +$6.76M
ARGX icon
6
argenx
ARGX
$52.5B
$11.4M 3.06%
15,500
-13,500
-47% -$8.9M
LQDA icon
7
Liquidia Corp
LQDA
$7.73B
$9.1M 2.43%
400,000
-620,000
-61% -$13.4M
PHVS icon
8
Pharvaris
PHVS
$2.33B
$8.62M 2.31%
345,381
+101,098
+41% +$2.24M
OCUL icon
9
Ocular Therapeutix
OCUL
$1.87B
$8.36M 2.24%
715,000
-102,699
-13% -$1.23M
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.38B
$7.64M 2.04%
104,262
-9,200
-8% -$585K
AGIO icon
11
Agios Pharmaceuticals
AGIO
$1.82B
$5.37M 1.44%
133,827
-5,905
-4% -$222K
KYMR icon
12
Kymera Therapeutics
KYMR
$8.47B
$5.24M 1.4%
92,592
-47,408
-34% -$2.14M
ELVN icon
13
Enliven Therapeutics
ELVN
$4.15B
$5.13M 1.37%
250,838
+5,000
+2% +$101K
CELC icon
14
Celcuity
CELC
$4.35B
$4.94M 1.32%
+100,000
New +$4M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.93B
$4.92M 1.32%
+125,000
New +$3.19M
IRON icon
16
Disc Medicine
IRON
$2.98B
$4.89M 1.31%
74,000
– –
QURE icon
17
uniQure
QURE
$2.99B
$4.38M 1.17%
+75,000
New +$1.36M
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$2.32B
$4.3M 1.15%
+316,312
New +$2.98M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.47B
$4.04M 1.08%
437,237
+24,941
+6% +$259K
ALLO icon
20
Allogene Therapeutics
ALLO
$635M
$3.7M 0.99%
2,981,396
+346,396
+13% +$413K
ASMB icon
21
Assembly Biosciences
ASMB
$512M
$3.46M 0.93%
+135,182
New +$2.97M
AVTX icon
22
Avalo Therapeutics
AVTX
$957M
$1.27M 0.34%
+100,000
New +$860K
CATX icon
23
Perspective Therapeutics
CATX
$354M
$1.2M 0.32%
+349,323
New +$1.27M
GERN icon
24
Geron
GERN
$853M
$1.16M 0.31%
845,000
+129,000
+18% +$172K
CGEM icon
25
Cullinan Oncology
CGEM
$1.05B
– –
-868,897
Closed -$6.54M
1
2

Similar funds

TCP
ThornTree Capital Partners Boston, Massachusetts $564M AUM 36.37% 1-Year Est. Return
AHSW
Adventist Health System West Roseville, California $564M AUM 17.1% 1-Year Est. Return
KF
KKM Financial Chicago, Illinois $563M AUM 28.2% 1-Year Est. Return
KBG
Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return
AAS
Asset Allocation Strategies Farmington, Michigan $563M AUM 15.65% 1-Year Est. Return
LC
Lavaca Capital Houston, Texas $564M AUM 4.6% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
OC
Opal Capital Boca Raton, Florida $565M AUM

Patient Square Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Patient Square Capital held 27 positions worth $374M, up 35% from $277M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Patient Square Capital's Q3 2025 filing shows 8 new, 6 increased, 8 reduced and 3 closed positions. Its largest new stake was Abivax: 151,833 shares worth $12.9M. The largest sale was Liquidia Corp, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Patient Square Capital's largest Q3 2025 buy was Abivax: 151,833 shares worth $12.9M.
  • Patient Square Capital added most to Cidara Therapeutics in Q3 2025, an estimated $6.76M increase.
  • Patient Square Capital's biggest Q3 2025 reduction was Liquidia Corp, cutting an estimated $13.4M.
  • Patient Square Capital fully exited Cullinan Oncology in Q3 2025, selling an estimated $6.54M.
  • Patient Square Capital's ten largest holdings make up 86% of its $374M portfolio in Q3 2025.
  • Patient Square Capital opened 8 new positions and closed 3 in Q3 2025.
  • Patient Square Capital's portfolio value rose 35% quarter-over-quarter to $374M.

Based on Patient Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.